Answers are grounded in this paper and cite their sources.
Aims ACT001, a novel sesquiterpene lactone derivative, is effective against treating glioblastoma multiforme and other diseases. This study aims to investigate its metabolic and excretion characteristics. Methods A single oral dose of 600 mg/200 μCi [ 14 C]ACT001 was administered to six healthy subjects. Blood, urine and fecal samples were collected and measured for total radioactivity (TRA), ACT001 and its main metabolite (monomethylamine micheliolide, MA‐MCL). The safety was also assessed. Results The mean elimination half‐life (t 1/2 ) of TRA, of TRA, ACT001 and MA‐MCL were 33.7 h, 3.16 h, and 8.45 h, respectively. ACT001 and MA‐MCL accounted for 14.49% and 30.50% of TRA, respectively. In addition, radiochromatographic profiling confirmed no other individual metabolite exceeded 2% of total peak area. The individual ratios of total radioactivity in whole blood relative to plasma ranged from 0.330 to 0.827. The primary excretion route of ACT001 was urine (accounting for 90.08% ± 1.16% of dose), with a small amount excreted in faeces (accounting for 7.30% ± 0.66% of dose), resulting in a total excretion rate of 97.39% ± 0.93%. Metabolites represented more than 80% of urinary excretion. The main metabolic pathways involved demethylation, oxidation, and dealkylation to form micheliolide and glucuronidation or cysteine conjugation of related metabolites. Conclusions [ 14 C]ACT001 was rapidly absorbed but slowly eliminated, as reflected by the longer elimination t 1/2 of TRA (33.7 h) vs . ACT001 (3.16 h) and MA‐MCL (8.45 h). The overall mass balance was nearly complete. ACT001 and MA‐MCL were the primary circulating compounds. Demethylated metabolites were the primary substances excreted in urine and faeces.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: